<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BECA2763-0902-40AA-8DB2-836A5731CF58"><gtr:id>BECA2763-0902-40AA-8DB2-836A5731CF58</gtr:id><gtr:name>Brunel University</gtr:name><gtr:address><gtr:line1>Brunel University</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>UB8 3PH</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6336EAC6-4CEE-4321-85B2-A4003F9C2894"><gtr:id>6336EAC6-4CEE-4321-85B2-A4003F9C2894</gtr:id><gtr:name>Experimental Cancer Medicine Centre Network (ECMC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F19D4E48-AE40-4A1A-B294-D6ECFB68B85F"><gtr:id>F19D4E48-AE40-4A1A-B294-D6ECFB68B85F</gtr:id><gtr:name>Varian Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/200B6370-0D75-4308-9CA2-EDC9C607FE12"><gtr:id>200B6370-0D75-4308-9CA2-EDC9C607FE12</gtr:id><gtr:name>Acuitas Medical Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/785B46C9-6DC4-48A2-93A7-B5E21890FF39"><gtr:id>785B46C9-6DC4-48A2-93A7-B5E21890FF39</gtr:id><gtr:name>Cancer Partners UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2D017FB7-303D-48E6-AAFF-06303F046804"><gtr:id>2D017FB7-303D-48E6-AAFF-06303F046804</gtr:id><gtr:name>Royal Marsden NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BECA2763-0902-40AA-8DB2-836A5731CF58"><gtr:id>BECA2763-0902-40AA-8DB2-836A5731CF58</gtr:id><gtr:name>Brunel University</gtr:name><gtr:address><gtr:line1>Brunel University</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>UB8 3PH</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6336EAC6-4CEE-4321-85B2-A4003F9C2894"><gtr:id>6336EAC6-4CEE-4321-85B2-A4003F9C2894</gtr:id><gtr:name>Experimental Cancer Medicine Centre Network (ECMC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F19D4E48-AE40-4A1A-B294-D6ECFB68B85F"><gtr:id>F19D4E48-AE40-4A1A-B294-D6ECFB68B85F</gtr:id><gtr:name>Varian Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/200B6370-0D75-4308-9CA2-EDC9C607FE12"><gtr:id>200B6370-0D75-4308-9CA2-EDC9C607FE12</gtr:id><gtr:name>Acuitas Medical Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/785B46C9-6DC4-48A2-93A7-B5E21890FF39"><gtr:id>785B46C9-6DC4-48A2-93A7-B5E21890FF39</gtr:id><gtr:name>Cancer Partners UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D017FB7-303D-48E6-AAFF-06303F046804"><gtr:id>2D017FB7-303D-48E6-AAFF-06303F046804</gtr:id><gtr:name>Royal Marsden NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B748BC98-AACE-466E-8823-111D91D3AC77"><gtr:id>B748BC98-AACE-466E-8823-111D91D3AC77</gtr:id><gtr:name>The Mount Vernon Hospital Trust</gtr:name><gtr:address><gtr:line1>The Mount Vernon Hospital Trust</gtr:line1><gtr:line2>Rickmansworth Road</gtr:line2><gtr:postCode>HA6 2RN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/78530B5E-56D0-4F6A-A087-6FDEB9688984"><gtr:id>78530B5E-56D0-4F6A-A087-6FDEB9688984</gtr:id><gtr:firstName>Roberto</gtr:firstName><gtr:surname>Alonzi</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701945"><gtr:id>84AD11B6-BD61-4942-848E-ECE3CF3EB79C</gtr:id><gtr:title>The development of magnetic resonance based hypoxia imaging for targeted radiotherapy planning.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701945</gtr:grantReference><gtr:abstractText>Cancer patients that have tumours with low oxygen levels (also known as hypoxic tumours) have a worse prognosis than those with well oxygenated tumours. They are more likely to relapse after treatment with radiotherapy or chemotherapy and a higher chance of developing incurable metastatic disease. 

Currently there is no practical method of measuring hypoxia in tumours prior to treatment. This project aims to build on current research in order to develop MRI based imaging of hypoxia as a feasible tool for routine clinical use. The research will predominately be carried out in patients will pelvic malignancies such as prostate and cervical cancer. In order to validate the imaging processes, the MRI maps of hypoxia will be compared with tissue samples obtained from patients during their planned cancer surgery. The hypoxia maps that are generated will then be used to target hypoxic tumour regions using highly focused radiotherapy.

The potential for clinical application is substantial. Hypoxia imaging could be incorporated into staging procedures to provide prognostic information. Strategies to combat hypoxia may be offered on an individualised basis and hypoxia maps offer the prospect of targeted treatments such as highly conformal radiotherapy with dose escalation to the hypoxic regions.


F3B Stem Cell Lay Summary - Before completing this section you MUST refer to the guidance notes. (Up to a maximum of 6 A4l sheets, explain to a lay audience the nature of the proposed research, the prospective outcomes and the expected benefits in terms of improvement to human health).</gtr:abstractText><gtr:technicalSummary>Background
Tumour hypoxia is a recognised cause of treatment failure. Currently there is no reliable method to measure and map the distribution of hypoxia before treatment begins, which has hampered the development of strategies to combat hypoxia. This project will build upon current research to develop MRI protocols that can generate high-resolution hypoxia maps of human tumours for use in routine clinical practice. The project will then proceed to targeting tumour hypoxia, guided by the MR derived hypoxia maps, using highly focused radiotherapy.
Relevance to cancer
The potential for clinical application is substantial. Hypoxia imaging could be incorporated into staging procedures to provide prognostic information. Strategies to combat hypoxia may be offered on an individualised basis and hypoxia maps offer the prospect of targeting treatment to hypoxic tumour regions.
Scientific Rational
Blood Oxygen Level Dependent (BOLD) MRI capitalizes on the differing magnetic properties of oxygenated and deoxygenated haemoglobin. Microscopic magnetic field gradients in the vicinity of perfused vessels are caused by changes in the deoxyhaemoglobin concentration, leading to signal changes in susceptibility-weighted MRI sequences. For BOLD-MRI to be able to depict tissue oxygenation status it is necessary to know that tissues are perfused by red blood cells. Combining MRI based blood volume measurements with BOLD imaging therefore reflects tissue oxygenation more accurately.
Specific aims of the research
To develop magnetic resonance based hypoxia imaging for targeted radiotherapy planning by:
1) Validating blood volume adjusted Blood Oxygen Dependent (BOLD) MRI hypoxia maps.
2) The development of radiobiological models for optimal radiotherapy delivery based on the MRI derived hypoxia maps.
3) Clinical implementation of highly conformal radiotherapy treatment to boost hypoxic targets.
Research Plan
Our previous research has demonstrated the potential for hypoxia imaging using MRI. However, current methodology is impractical for routine clinical use. The first series of experiments will evaluate alternative strategies to generate MR derived blood volume data from human tumours that can then be combined with BOLD images to generate hypoxia maps. 

We will develop radiobiological models to show the advantage of selective radiation dose escalation in enhancing tumor control probability by targeting hypoxic tumour regions.

Highly conformal HDR brachytherapy will be used to target hypoxic areas in a dose-escalation clinical trial for patients with prostate cancer. A protocol for this study has already been written. A dose escalation scheme to hypoxic tumour sub-volumes has been calculated using biologically equivalent dose estimations derived from the linear-quadratic model.</gtr:technicalSummary><gtr:fund><gtr:end>2013-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>897750</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CRUK and EPSRC Cancer Imaging Group, Royal Marsden NHS Foundation Trust</gtr:description><gtr:id>8284F0AB-E0C5-45CE-885E-0E976460D504</gtr:id><gtr:impact>OUTPUTS: 3 Peer-Reviewed original research papers: Pubmed IDs 19190629, 20578023, 20630668 (see publications section). 9 Conference proceedings at international conferences.

Multidisciplinary Collaboration: Clinical Oncology, Radiobiology, Radiology, Physics, Computer Software Development.

Some software outputs from this collaboration have commercial potential</gtr:impact><gtr:outcomeId>12A983C0A9B-1</gtr:outcomeId><gtr:partnerContribution>This group provides the software development and MR analysis tools as well as valuable technical MR expertise that allows our work to remain at the forefront of Magnetic Resonance research</gtr:partnerContribution><gtr:piContribution>We design and carry out the research studies that are supported by the technical expertise of our collaborators</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Barts and The London School of Medicine and Dentistry</gtr:department><gtr:description>Tahereh Kamalati - Barts and The London School of Medicine</gtr:description><gtr:id>9EC1CC48-74A1-4A1C-AC6A-BB4F795C501E</gtr:id><gtr:impact>Results awaited.</gtr:impact><gtr:outcomeId>rwn9AC7jXXP-1</gtr:outcomeId><gtr:partnerContribution>Access to novel therapeutics for prospective testing in the clinical trial setting</gtr:partnerContribution><gtr:piContribution>The development of scFv antibodies as therapeutics for in vivo targeting of prostate cancer.

Clinical sample collection, handling and processing. Retrospective and Prospective collection and analysis of data. Intellectual Input.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Experimental Cancer Medicine Centre Network (ECMC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECMC/AstraZeneca/CRUK Combinations Alliance</gtr:description><gtr:id>A76DD8F1-92AC-4E09-9890-DC6ACBEEF922</gtr:id><gtr:impact>The collaboration involves radiotherapy (our group), industry (AstraZeneca), radiology (Mt Vernon), the immunohistochemistry group at University College London and the Combinations Alliance Team at CRUK.</gtr:impact><gtr:outcomeId>oa97u7qbrBR-3</gtr:outcomeId><gtr:partnerContribution>This partnership will eventually fund a set-up cost of &amp;pound;70,000 plus &amp;pound;2000 per patient recruited to our next trial of biological sensitisation during prostate radiotherapy. The partnership also facilitates the set-up and administration of the trial through the CRUK combinations alliance teamThis partnership will eventually fund a set-up cost of &amp;pound;70,000 plus &amp;pound;2000 per patient recruited to our next trial of biological sensitisation during prostate radiotherapy. The partnership also facilitates the set-up and administration of the trial through the CRUK combinations alliance teamThis partnership will eventually fund a set-up cost of &amp;pound;70,000 plus &amp;pound;2000 per patient recruited to our next trial of biological sensitisation during prostate radiotherapy. The partnership also facilitates the set-up and administration of the trial through the CRUK combinations alliance team</gtr:partnerContribution><gtr:piContribution>As part of our work on hypoxia modification during prostate radiotherapy we are interested in evaluating the role of PARP inhibition (which is know to modulate tumour vasculature in pre-clinical prostate models) during prostate radiotherapy. We have designed a Phase I study to evaluate the tolerability and efficacy in humans</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Manchester Cancer Research Centre</gtr:department><gtr:description>PRONIM</gtr:description><gtr:id>F083DB99-C683-4E6E-B7FD-B7C75ED0440F</gtr:id><gtr:impact>Grant application</gtr:impact><gtr:outcomeId>5463d3740ec9a3.52929375-1</gtr:outcomeId><gtr:partnerContribution>As above</gtr:partnerContribution><gtr:piContribution>Collaboration that has led to the development of a phase III clinical trial for hypoxia modification in prostate cancer. CTAAC application in process.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Varian Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Varian Medical Systems (industry)</gtr:description><gtr:id>E2AFBA5C-177D-4C2F-AF64-1DBD721607E1</gtr:id><gtr:impact>Commencement of a phase II clinical trial</gtr:impact><gtr:outcomeId>SZoadqiG3Yb-1</gtr:outcomeId><gtr:partnerContribution>Varian are developing computer software to incorporate biological data into the planning process and have also been a source of advise regarding some of the technical aspects of the project</gtr:partnerContribution><gtr:piContribution>The major work for the current MRC grant involves the use ofr high dose rate brachytherapy for biological radiotherapy planning. Our group is driving the science and clinical development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECMC/AstraZeneca/CRUK Combinations Alliance</gtr:description><gtr:id>E6954009-2E34-4C5F-9E3F-4B463295BD06</gtr:id><gtr:impact>The collaboration involves radiotherapy (our group), industry (AstraZeneca), radiology (Mt Vernon), the immunohistochemistry group at University College London and the Combinations Alliance Team at CRUK.</gtr:impact><gtr:outcomeId>oa97u7qbrBR-2</gtr:outcomeId><gtr:partnerContribution>This partnership will eventually fund a set-up cost of &amp;pound;70,000 plus &amp;pound;2000 per patient recruited to our next trial of biological sensitisation during prostate radiotherapy. The partnership also facilitates the set-up and administration of the trial through the CRUK combinations alliance teamThis partnership will eventually fund a set-up cost of &amp;pound;70,000 plus &amp;pound;2000 per patient recruited to our next trial of biological sensitisation during prostate radiotherapy. The partnership also facilitates the set-up and administration of the trial through the CRUK combinations alliance teamThis partnership will eventually fund a set-up cost of &amp;pound;70,000 plus &amp;pound;2000 per patient recruited to our next trial of biological sensitisation during prostate radiotherapy. The partnership also facilitates the set-up and administration of the trial through the CRUK combinations alliance team</gtr:partnerContribution><gtr:piContribution>As part of our work on hypoxia modification during prostate radiotherapy we are interested in evaluating the role of PARP inhibition (which is know to modulate tumour vasculature in pre-clinical prostate models) during prostate radiotherapy. We have designed a Phase I study to evaluate the tolerability and efficacy in humans</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Acuitas Medical Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Acuitas Medical (industry)</gtr:description><gtr:id>5AA7737A-9ED9-48E5-97DA-2AB1BFC6D67A</gtr:id><gtr:impact>A financial contribution has been made with further financial contributions to be made for each patient imaged with the new sequences.

Acuitas Medical seek to exploit this research commercially.

Multi-disciplinary: Radiology, Clinical Oncology, Physics and Industry</gtr:impact><gtr:outcomeId>X3ZvwJBohXy-1</gtr:outcomeId><gtr:partnerContribution>The provision of new imaging sequences for incorporation into prospective evaluation of prostate cancer</gtr:partnerContribution><gtr:piContribution>The main goal of this MRC funded research is to design and incorporate novel imaging sequences into the radiotherapy planning process that will allow individualised radiotherapy planning based on specific tumour biology. This collaboration has provided access to a completely new type of magnetic resonance imaging sequence which we will be the first to test in Prostate Cancer.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Northern Institute for Cancer Research Newcastle</gtr:department><gtr:description>Ross Maxwell</gtr:description><gtr:id>0DD8A12A-606C-4B7C-AA88-308D3966226E</gtr:id><gtr:impact>Outputs: 1 peer-reviewed original research paper: Pubmed ID 19190629
1 manuscript in preparation

Multidisciplinary: Clinical oncology and Magnetic Resonance Physics</gtr:impact><gtr:outcomeId>G4vud2SmBVz-1</gtr:outcomeId><gtr:partnerContribution>Essential technical contribution for the analysis of Blood Oxygen Level Dependent magnetic resonance imaging data.</gtr:partnerContribution><gtr:piContribution>The generation and interpretation of Blood Oxygen Level Dependent MRI data is critical to almost all aspects of this MRC funded research program. My research team dedicates much of its time to this form of hypoxia imaging for the purpose of incorporating these sequences into the radiotherapy planning process. Ross Maxwell has a long standing track-record in this area and provides invaluable advise to our group, including writing and editing computer algorithms to interpret the imaging data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Research Department of Urology, University College London</gtr:description><gtr:id>BBBA57D2-F2C1-49DB-B9DC-4AB35DD02856</gtr:id><gtr:impact>We have arranged a project / protocol development group that has met several times. We have made 2 joint grant applications. We have arranged 2 patient focus group meetings</gtr:impact><gtr:outcomeId>HW1b7aUdSGH-1</gtr:outcomeId><gtr:partnerContribution>The Urology team is providing the highly focused ultrasound (HIFU) input to the project</gtr:partnerContribution><gtr:piContribution>This collaboration is based around biologically optimised focal therapy for prostate cancer. Our group is providing the radiotherapy input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brunel University London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biosciences</gtr:department><gtr:description>Brunel University</gtr:description><gtr:id>89FCC22A-ADD7-4E8F-8E81-856126DEB564</gtr:id><gtr:impact>A grant application has been made (awaiting outcome)</gtr:impact><gtr:outcomeId>JpwTXaTiSEA-1</gtr:outcomeId><gtr:partnerContribution>Brunel have basic science expertise and the required laboratory equipment</gtr:partnerContribution><gtr:piContribution>Out clinical and translation radiotherapy expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Leicester</gtr:description><gtr:id>F128A90E-446F-4181-A7E8-6838D61B4C43</gtr:id><gtr:impact>Multidisciplinary involving oncology, urology, genetics and immunohistochemistry. First publication expected Summer 2012</gtr:impact><gtr:outcomeId>BohuU93RYih-1</gtr:outcomeId><gtr:partnerContribution>Exploration of the role of novel prognostic and predictive biomarkers in prostate cancer that may be exploitable in the setting of biologically targeted radiotherapy</gtr:partnerContribution><gtr:piContribution>Our group is investigating the role of novel biomarkers that may be useful to direct biologically targeted prostate radiotherrapy. The group from Leicester have access to 2 new antibodies that are directed at gene-fusion products that are upregulated in prostate cancer and may be a surrogate for an aggressive phenotype. Our groups are working together to combine our clinical and tissue resources with their new antibodies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ECMC/AstraZeneca/CRUK Combinations Alliance</gtr:description><gtr:id>4FC4090B-8094-4E88-96F3-49C293FFC861</gtr:id><gtr:impact>The collaboration involves radiotherapy (our group), industry (AstraZeneca), radiology (Mt Vernon), the immunohistochemistry group at University College London and the Combinations Alliance Team at CRUK.</gtr:impact><gtr:outcomeId>oa97u7qbrBR-1</gtr:outcomeId><gtr:partnerContribution>This partnership will eventually fund a set-up cost of &amp;pound;70,000 plus &amp;pound;2000 per patient recruited to our next trial of biological sensitisation during prostate radiotherapy. The partnership also facilitates the set-up and administration of the trial through the CRUK combinations alliance teamThis partnership will eventually fund a set-up cost of &amp;pound;70,000 plus &amp;pound;2000 per patient recruited to our next trial of biological sensitisation during prostate radiotherapy. The partnership also facilitates the set-up and administration of the trial through the CRUK combinations alliance teamThis partnership will eventually fund a set-up cost of &amp;pound;70,000 plus &amp;pound;2000 per patient recruited to our next trial of biological sensitisation during prostate radiotherapy. The partnership also facilitates the set-up and administration of the trial through the CRUK combinations alliance team</gtr:partnerContribution><gtr:piContribution>As part of our work on hypoxia modification during prostate radiotherapy we are interested in evaluating the role of PARP inhibition (which is know to modulate tumour vasculature in pre-clinical prostate models) during prostate radiotherapy. We have designed a Phase I study to evaluate the tolerability and efficacy in humans</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Partners UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Radiotherapy</gtr:department><gtr:description>Cancer Partners UK (industry)</gtr:description><gtr:id>4D8947FE-9FD2-412D-B8B9-C2EFFD6DA8CC</gtr:id><gtr:impact>Agreements only signed 2 weeks ago</gtr:impact><gtr:outcomeId>FRN3nGRhdQD-1</gtr:outcomeId><gtr:partnerContribution>Host the data
IT support
Financial backing</gtr:partnerContribution><gtr:piContribution>Evaluation of Image Guidance during radiation delivery for the improvement of precision radiotherapy</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Marsden NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Academic Urology Unit</gtr:department><gtr:description>Academic Urology Unit, Royal Marsden NHS Trust</gtr:description><gtr:id>3D70A8B6-48A6-4DA2-85A5-6C07FA1F5172</gtr:id><gtr:impact>2 trial protocols in development (one phase II, one phase III)
2 manuscripts in preparation</gtr:impact><gtr:outcomeId>FDoeUdnBzzd-1</gtr:outcomeId><gtr:partnerContribution>Essential technical input for the delivery of precision radiotherapy for focal dose escalation in prostate cancer.

We are combining two large prospective datasets (one from the Royal Marsden and one of our own) for the purpose of biomarker development in prostate cancer</gtr:partnerContribution><gtr:piContribution>3 major areas of collaboration:
A) Osteopontin as a prognostic and predictive biomarker for prostate cancer
B) The role of stereotactic body radiotherapy for prostate cancer
C) The use of highly conformal radiotherapy techniques for focal dose escalation in prostate cancer</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Consensus meeting on whole body diffusion weighted imaging in MRI</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>619CEE15-C756-41E2-B8BB-D10DA704F852</gtr:id><gtr:impact>This consensus meeting was to construct the UK national guidelines for whole body diffusion weighted imaging in MRI which are now ready for publication</gtr:impact><gtr:outcomeId>58c95cd5ca2770.18641601</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Guy's Hospital Focal Brachytherapy</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>83EBE11F-F660-4CB6-86C5-DB82399DCAF7</gtr:id><gtr:impact>Working group to design a collaborative national trial for focal seed prostate brachytherapy

Trial Protocol is in development</gtr:impact><gtr:outcomeId>dh3jGJ5SBKy</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prostate Cancer Charity Christmas Advertising Campaign</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3B160DEB-E41E-463E-A303-FEE759EC7521</gtr:id><gtr:impact>The Prostate Cancer Charity has chosen to focus on our research as the basis for their Christmas advertising campaign. This has involved interviews, photography and the production of a pack that will be sent to many thousands of homes at Christmas time with an interview transcript, card and an illustrated summary of the research

Fundraising</gtr:impact><gtr:outcomeId>PsCSdB6HGV5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Training for the Pharmaceutical Industry</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>428E4D41-4E14-40A9-897B-127E9537E54B</gtr:id><gtr:impact>Lecture / Discussion to 30-40 members of phamaceutical industry including management, executives and research staff. The presentation outlines the continued importance of radiotherapy to a drug focussed industry. It also highlighted the need for further collaboration between the pharaceutical industry and the radiotherapy community

Increased awareness</gtr:impact><gtr:outcomeId>85C06A08FF6</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Promotional Video</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0A1979DA-D6B1-45E8-8EDA-B83A6CFC3851</gtr:id><gtr:impact>The video has been shown at a number of public events, fundraisers and national conferences

A good deal of public interest including numerous offers to participate in our clinical trials from newly diagnosed patients (all from UK)</gtr:impact><gtr:outcomeId>CvAeqKQWy6J</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Bushey Film</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>34EE7EB9-BC3C-42DE-865C-48510B2C7265</gtr:id><gtr:impact>Short film about prostate radiotherapy and brachytherapy for online dissemination

None yet</gtr:impact><gtr:outcomeId>MB75CD9KkfU</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Carbogen Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>877BC6A3-E975-496C-A654-92328529534C</gtr:id><gtr:impact>We promoted the concept of hypoxia modification during radiotherapy by inviting interested departments to come and see the technique for themselves

More departments using carbogen - which will boost recruitment to future trials using this technique</gtr:impact><gtr:outcomeId>bciKsbZcS58</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Focal Therapy Workshop - RSM</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EE6FB55E-2F31-430D-81B3-8773F159E681</gtr:id><gtr:impact>A panel of international prostate cancer specialists with an interest in promoting focal therapies

Consensus document in preparation for publication</gtr:impact><gtr:outcomeId>jKguXNSBatY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>East of England Study Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6959CA64-E2D7-4A80-8373-76F97F632FAD</gtr:id><gtr:impact>Regional educational day on prostate cancer for a very wide audience</gtr:impact><gtr:outcomeId>58c95c4cc68305.07721800</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Regional Urological Oncology Education Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7847B3EB-E953-4856-9DD9-7A296D1FD517</gtr:id><gtr:impact>A meeting of regional urological oncologists with invited international colleagues. Many talks which promoted discussion

May lead to international collaboration</gtr:impact><gtr:outcomeId>5463da927b4f18.24807214</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GP masterclass</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BE99163C-9457-430F-BE5E-748E994659F3</gtr:id><gtr:impact>Promoted the research to regional primary care physicians with an emphasis on facilitating trial recruitment

I have been asked to give another presentation soon</gtr:impact><gtr:outcomeId>DPzWYxZkVqK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GP masterclass</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B6C6F4C8-3E2F-4153-9E16-B3448352CA22</gtr:id><gtr:impact>Presentation about prostate radiotherapy

Increased GP awareness</gtr:impact><gtr:outcomeId>cpN1FDoBF51</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture at UK &amp; Ireland Prostate Brachytherapy Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3A0DF1A8-B352-4DE8-B8AA-EB2A61062265</gtr:id><gtr:impact>Annual UK brachytherapy meeting. My research was highlighted leading to interest from other colleagues</gtr:impact><gtr:outcomeId>58c95d62227867.49762471</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mount Vernon Prostate Cancer Patient Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B3BA5239-2F94-4214-BC86-1AF05CC6913D</gtr:id><gtr:impact>Talk about research in prostate cancer that is occurring at Mt Vernon Cancer Centre. Question and answer sessions.

These talks occur monthly. I direct the session 2-3 times per year

Patient awareness</gtr:impact><gtr:outcomeId>bdEVR9s3H9Q</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESTRO IGRT Course</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>23EB8A73-22DD-4429-A26C-024299098F63</gtr:id><gtr:impact>About 100 people attended. I presented a lecture which was followed by 2 other lectures. Subsequently we hosted an afternoon practical workshop on image guided radiotherapy

We are awaiting the formal feedback from delegates but there was very positive feedback on the day</gtr:impact><gtr:outcomeId>WWE1GTSykNT</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>YouTube video and promotional activity</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BBA96824-DF87-4BEA-B6BB-9B0B586A5436</gtr:id><gtr:impact>As part of the Prostate Cancer Charity Research in Action programme one of my talks was recorded and put on YouTube. Also I was interviewed and clips have been used in a number of advertising campaigns and promotional activities

Public Awareness

Referrals for trial participation</gtr:impact><gtr:outcomeId>quJ3D3mtmhX</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESTRO 2013 Geneva</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F926BE5F-F10F-4027-95B1-98E5A924FDF6</gtr:id><gtr:impact>Presentation of our most recent data. Showcase of our research program

Discussion about possible collaborations with 2 other UK universities (on-going discussion)</gtr:impact><gtr:outcomeId>QBZQS9of4e8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prostate Cancer Charity Fund-raising Dinners</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D6FC630A-D283-43CB-9ABC-523453B75334</gtr:id><gtr:impact>The Prostate Cancer Charity invites approximately 200 of its major donors to attend a function/dinner to allow interaction and discussion about prostate cancer research. Public, media and politicians are present and have the opportunity to interact and question prostate cancer researchers about their work.

I understand that a considerable amount of money is raised for the Prostate Cancer Charity at these events.</gtr:impact><gtr:outcomeId>jFtZqFDdkfa</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Prostate Cancer Charity National Research Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>05020396-A84F-43DA-90D8-EB150F12FB0C</gtr:id><gtr:impact>One day of this conference was for patients / public / media / user groups. I gave one of a series of 5 or 6 lectures which were recorded for presentation on the internet. There was also time for questions and discussion. Over 1000 people attended

Public awareness.</gtr:impact><gtr:outcomeId>Gqoyy8Aw1y6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prostate Cancer Study Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EEC7C9C3-B1D1-40CE-A6FF-A6DCB89B5045</gtr:id><gtr:impact>A study day hosted by our institution open to all (public, patients, nurses, allied health professionals etc). Attended by 150-200. Education event about all aspects of prostate cancer but highlighting new developments and the research taking place at our institution.

Raised community awareness. Repeat event scheduled annually</gtr:impact><gtr:outcomeId>38430603ED5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ONConnect Meeting - Romania</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2126309F-D8BA-4C10-BE34-07CCF321E447</gtr:id><gtr:impact>I was invited to the annual Romanian oncology forum. Most Romanian oncologists attend this meeting. I chaired sessions and gave 4 lectures showcasing the work we have been doing at Mt Vernon. A lot of focus was placed on helping Romanian departments to engage in this type of work</gtr:impact><gtr:outcomeId>58c95e15c56741.84490293</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Focal Salvage Film</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4248A663-D61F-4CCD-939C-F8A9F16B5A2E</gtr:id><gtr:impact>Film about prostate focal salvage therapies. Shown at various conferences and is available to view online. Currently on YouTube

Numerous referrals for our trial that has been funded by PC-UK (see further funding section)</gtr:impact><gtr:outcomeId>YJHsF6rR15b</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4505F48A-AACE-4EFE-BB67-83B5F5C09C99</gtr:id><gtr:impact>News and progress about his research features in the regular newsletter produced by the Marie Curie Research Fund at Mount Vernon Cancer Centre and is distributed to patients and the public

Public engagement, questions and donations</gtr:impact><gtr:outcomeId>auoFbeERzDu</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GP education seminar - London</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CF7D03E1-114A-420E-B0A8-7E5F268279B0</gtr:id><gtr:impact>Presentation followed by question and answer session discussing the need for further research in prostate cancer and the benefits and drawbacks for patients entering clinical trials. Specific mention of this research aimed to promote recruitment

Encouragement to engage in research and recommend clinical trials to their patients. Small financial conribution to our research fund.</gtr:impact><gtr:outcomeId>23A66925C99</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>12000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Royal College of Radiologists</gtr:department><gtr:description>Royal College of Radiologists Small Project Grants Scheme</gtr:description><gtr:end>2010-11-02</gtr:end><gtr:fundingOrg>Academy of Medical Royal Colleges</gtr:fundingOrg><gtr:id>D7DB7470-6F2A-4DFF-AD21-918E9B34D8B0</gtr:id><gtr:outcomeId>DF5D34DEA5F0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Kodak Radiology Fund Education Bursary</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Eastman Kodak Company (Kodak)</gtr:fundingOrg><gtr:id>09A53920-DA2C-4453-AFA9-2A30AFB9471B</gtr:id><gtr:outcomeId>CV7JNfZYWMr</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>118365</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Partners UK, project grant</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Cancer Partners UK</gtr:fundingOrg><gtr:id>CE417376-8A87-4978-981F-ECAAE4B4CF3E</gtr:id><gtr:outcomeId>pZ19nJuJ5W9</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240721</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate Cancer Charity - Project grant</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>PG09-38</gtr:fundingRef><gtr:id>93D52DE1-F2BA-4B0C-9C0E-D80B2C7B5D21</gtr:id><gtr:outcomeId>SojNZXRTgCH0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>188614</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate Cancer UK - College of Radiographers Clinical Research Training Fellowship</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>COR CRTF12-007</gtr:fundingRef><gtr:id>275FCA98-C6A6-4B28-ACDC-25C310047AD8</gtr:id><gtr:outcomeId>RTra9vqxDnr</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A number of attempts have been made to use imaging techniques to measure and map tumour hypoxia. Our method is the first MRI based technique to overcome certain technical difficulties related to blood flow and provides a non-invasive tool to quantitatively measure tumour hypoxia. The resulting imaging biomarkers can be used as prognostic and predictive measures as well as to assess response to various interventions</gtr:description><gtr:grantRef>G0701945</gtr:grantRef><gtr:id>63597C01-EC7F-41A5-ABDE-4E965A8D9A4D</gtr:id><gtr:impact>The technique has been incorporated into a number of study protocols</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>14A4DAC3381</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>MRI based hypoxia imaging technique</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Focal Therapy Consensus Document</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>108C7E08-9C04-4182-A897-FC6555AF369E</gtr:id><gtr:outcomeId>5463db47780500.55139218</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI Bladder Chemo-Radiation Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F7CC57BC-2649-4BF9-8BC9-65440B1F8A3D</gtr:id><gtr:impact>This group evaluates research studies that are submitted to the National Cancer Research Initiative for peer-review.</gtr:impact><gtr:outcomeId>fsCWZG1fu5F</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI CTRad Preclinical and Translational Workstream</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6C355666-CEA0-4BA1-9218-359E0EFD1B7A</gtr:id><gtr:impact>CTRad is an NCRI working group set up in 2009 to focus on clinical and translational issues relating to radiotherapy and radiobiology, as well as developing a portfolio of practice-changing trials. CTRad has also been tasked with actively promoting translation of new discoveries into practice.</gtr:impact><gtr:outcomeId>EB2z69tLFjr</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI WS1</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2E0E949C-D662-497E-92B6-B57A8D5DD8AA</gtr:id><gtr:outcomeId>DSAoYh9eVqk</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI low-risk Prostate Cancer Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5B551CDA-0E0C-4773-B14C-5D699F820E71</gtr:id><gtr:impact>This group evaluates research studies that are submitted to the National Cancer Research Initiative for peer-review.</gtr:impact><gtr:outcomeId>RxDALroueWm</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Experimental Cancer Medicine Centres (ECMC) Imaging Network</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7EEA4AFA-5CE8-4173-A426-B04CBC7914F4</gtr:id><gtr:impact>the development of this first set of consensus guidelines that will further aid the application of DCE-CT to the evaluation of tumour vascular physiology. These guidelines were developed from the results of a 2-round Delphi process involving 10 experts in DCE-CT (4 UK and 6 international), followed by a 2 day face-to-face meeting of 8 of the participants, along with 2 representative oncologists with an interest in the application of DCE-CT. The meeting formed part of the proceedings of an Experimental Cancer Medicine Centres (ECMC) Imaging Network workshop held at the Royal College of Physicians, London,</gtr:impact><gtr:outcomeId>qAgipUm5J15</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The addition of Nicotinamide and Carbogen Gas breathing during radical radiotherapy for high risk prostate cancer.
Phase II completed
Phase III in preparation</gtr:description><gtr:id>4184FC60-190D-45DC-B7C1-0D5BB75847B3</gtr:id><gtr:impact>Imaging biomarkers for the presence of hypoxia in prostate tumours</gtr:impact><gtr:outcomeId>5463e07d2a9259.79661096</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PROCON</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:ukcrnIsctnId>08912168</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The use of multiparametric MRI to direct focal boosting of biologically relevant tumour deposits within the prostate gland
This was the primary objective of this MRC grant</gtr:description><gtr:id>433CCCB1-FFD2-431E-B28F-8A837D23E594</gtr:id><gtr:impact>Refinement of brachytherapy technique
Now being used in routine clinical practice in some centres</gtr:impact><gtr:outcomeId>5463e21fe45ce1.78273671</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Focussed HDR brachytherapy boost for localised prostate cancer</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Our group is continually refining and developing new magnetic resonance imaging sequences and protocols to establish novel imaging biomarkers for the assessment of disease and response to treatment for prostate cancer. These biomarkers are related to tumour hypoxia, vascular dynamics, blood flow, cellularity, cell death and metabolism.</gtr:description><gtr:id>74781FCB-BA8D-4092-8D12-2018EAF012A9</gtr:id><gtr:impact>These sequences and protocols have been incorporated into trial protocols for studies of various tumour types at our own and other UK cancer centres.</gtr:impact><gtr:outcomeId>He7eFSEbxf7</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Novel imaging biomarkers</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Tissue Bank of prostate cancer samples linked to mature outcome data. Approximately 350 samples</gtr:description><gtr:id>EDB5B44B-CF05-4528-93DA-696BB4F3BB4C</gtr:id><gtr:impact>2 biomarker studies. one with Leicester University - analysis ongoing. 1 with Royal Marsden Hospital - analysis complete, manuscript in preparation</gtr:impact><gtr:outcomeId>HGh4nAre61S</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Prostate Tissue Bank</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A novel method of imaging tumour hypoxia using combined functional MRI. Quantitative data taken from two seperate MRI techniques have been combined to produce tumour hypoxia maps. The technique has been validated against immunohistochemical controls</gtr:description><gtr:id>79A49927-87D1-47AC-9BD8-B57994AE3A94</gtr:id><gtr:impact>The technique has been used to quantitavely assess oxygenation changes in the prostate following a number of different interventions. Several conference proceedings have resulted as well as the publications listed in section 1</gtr:impact><gtr:outcomeId>4675BAFB435</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Hypoxia Imaging using MRI</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Combination of prostate template biopsy, multiparametric prostate MRI and choline PET to direct focal salvage therapy for radiorecurrent prostate cancer</gtr:description><gtr:id>4AE4EC16-46BF-4F83-B309-CC1398946DDD</gtr:id><gtr:impact>Successful funding application to PCUK. Phase II trial underway</gtr:impact><gtr:outcomeId>5463dcb97694e9.14423883</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Salvage HDR brachytherapy</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6552E811-CE3F-4085-82CB-D05ECFE458D6</gtr:id><gtr:title>Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86448c064dcecdaa1a7c75f46d33e8a2"><gtr:id>86448c064dcecdaa1a7c75f46d33e8a2</gtr:id><gtr:otherNames>Alonzi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>hgvLi9mVyN3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F92DD208-83A6-4C66-9099-CFA1571F7EE4</gtr:id><gtr:title>Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate.</gtr:title><gtr:parentPublicationTitle>Journal of magnetic resonance imaging : JMRI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86448c064dcecdaa1a7c75f46d33e8a2"><gtr:id>86448c064dcecdaa1a7c75f46d33e8a2</gtr:id><gtr:otherNames>Alonzi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-1807</gtr:issn><gtr:outcomeId>FRaPf331tG1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DCF1B93-EBD7-49D9-8C43-44E501CE8893</gtr:id><gtr:title>Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography.</gtr:title><gtr:parentPublicationTitle>European radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3b58f2fff46294170c79b5cdbdbfe02"><gtr:id>c3b58f2fff46294170c79b5cdbdbfe02</gtr:id><gtr:otherNames>Miles KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0938-7994</gtr:issn><gtr:outcomeId>s33bARbc89F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30EAD2E3-F85A-4A20-89EE-14196B0CAAD6</gtr:id><gtr:title>High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94bc5020b12c8eb71078039f363be948"><gtr:id>94bc5020b12c8eb71078039f363be948</gtr:id><gtr:otherNames>Hoskin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5463d2178c9991.78327070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CBF3092-C1D9-4FC8-A6F8-9051925DAD55</gtr:id><gtr:title>Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86448c064dcecdaa1a7c75f46d33e8a2"><gtr:id>86448c064dcecdaa1a7c75f46d33e8a2</gtr:id><gtr:otherNames>Alonzi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>3A25DA02643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6953630E-8663-464C-AF2A-329C5AA035DC</gtr:id><gtr:title>Image-guided radiotherapy for prostate cancer in the United Kingdom: a national survey.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51811d250152300a6c20e330cc4872cc"><gtr:id>51811d250152300a6c20e330cc4872cc</gtr:id><gtr:otherNames>Ariyaratne H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>58c95b34e95521.66169052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDF1FCC5-9C04-46BF-B1FF-523570F7A6B7</gtr:id><gtr:title>Carbogen gas and radiotherapy outcomes in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Therapeutic advances in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96789f1684bcf046752e47fe65803067"><gtr:id>96789f1684bcf046752e47fe65803067</gtr:id><gtr:otherNames>Yip K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1756-2872</gtr:issn><gtr:outcomeId>n7WgNQsyN2Z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FD4EDA6-C14D-49FD-AFFA-C36DF3AB1136</gtr:id><gtr:title>Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>European radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29f6de02486ed9d05abbabdb3019f1b2"><gtr:id>29f6de02486ed9d05abbabdb3019f1b2</gtr:id><gtr:otherNames>Leach MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0938-7994</gtr:issn><gtr:outcomeId>tMACsPoBzRP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F91342C8-4FED-443B-A01E-04C166A78C65</gtr:id><gtr:title>The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07974393a1323ce5b170d4afa1ebf29e"><gtr:id>07974393a1323ce5b170d4afa1ebf29e</gtr:id><gtr:otherNames>Le H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>pm_16451_21_23849693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>928E9F01-905A-48E4-837D-CD9DEF6A6BF9</gtr:id><gtr:title>Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0fe5a60f395d6b3c7d013a1b82df6be"><gtr:id>c0fe5a60f395d6b3c7d013a1b82df6be</gtr:id><gtr:otherNames>Ng QS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>fK1vd4nDsPe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EE73C61-C878-479D-85C2-D096CBB1DBD0</gtr:id><gtr:title>Image-guided radiotherapy for prostate cancer with cone beam CT: dosimetric effects of imaging frequency and PTV margin.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51811d250152300a6c20e330cc4872cc"><gtr:id>51811d250152300a6c20e330cc4872cc</gtr:id><gtr:otherNames>Ariyaratne H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>58c95b34bda1a0.79821365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DEB261E-7947-4BC8-9CD5-BD38EE9D577D</gtr:id><gtr:title>Optimal source distribution for focal boosts using high dose rate (HDR) brachytherapy alone in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f264952760564c58993296057bd6e6cc"><gtr:id>f264952760564c58993296057bd6e6cc</gtr:id><gtr:otherNames>Dankulchai P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5463d217b1e327.00017551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65E1F74E-5283-43E5-9232-60E181433C7D</gtr:id><gtr:title>Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe5e9c2c85f1431b1dc66f938326d3eb"><gtr:id>fe5e9c2c85f1431b1dc66f938326d3eb</gtr:id><gtr:otherNames>Donaldson IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5463d217ded339.39999039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC76C66E-EB00-422A-A83D-36922F73C89B</gtr:id><gtr:title>High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94bc5020b12c8eb71078039f363be948"><gtr:id>94bc5020b12c8eb71078039f363be948</gtr:id><gtr:otherNames>Hoskin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5463d217675638.23652383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D92C8C4-9C6B-4460-8978-6E1DE8231285</gtr:id><gtr:title>Hypofractionated radiotherapy for localized prostate cancer using three-dimensional conformal radiotherapy technique: 3 years toxicity analysis.</gtr:title><gtr:parentPublicationTitle>Indian journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da8ffc29a5c3678e08a1a5f82204a9d2"><gtr:id>da8ffc29a5c3678e08a1a5f82204a9d2</gtr:id><gtr:otherNames>White R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0019-509X</gtr:issn><gtr:outcomeId>58c95b348ffb19.70577932</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701945</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>